Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Verastem Oncology Receives FDA Breakthrough Therapy Designation For VS-6766 With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer


Benzinga | May 24, 2021 07:04AM EDT

Verastem Oncology Receives FDA Breakthrough Therapy Designation For VS-6766 With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC